Delattre B, Cormier L, Borgogno C, Descotes J L, Peiffert D, Hannoun-Levi J M, Moreau J L
Service d'urologie, université de Bourgogne, CHU de Dijon, 21000 Dijon, France.
Service d'urologie, université de Bourgogne, CHU de Dijon, 21000 Dijon, France.
Prog Urol. 2017 Oct;27(12):626-631. doi: 10.1016/j.purol.2017.05.008. Epub 2017 Jun 23.
Prostate cancer brachytherapy can be used as an alternative to the radical prostatectomy and radiotherapy. In the low-risk group, specific survivals are up to 95% after 10years. The aim of the study is to describe the practices in brachytherapy in France.
A survey made by AFU (French Urologic Association) and SFRO (French Society Of Oncological Radiotherapy) assessing the practices in brachytherapy in France was sent to all the urologists and radiotherapists even if they did not practice it.
In total, 1417 surveys were sent, 285 were received coming from 211 urologists (74%) and 74 radiotherapists (26%). Sixty (21%) practiced brachytherapy (31 urologists, 29 radiotherapists). Low dose rate with permanent implants was used in 83,3%. Brachytherapy was advised for low-risk group by 90% who responded the survey, 73% used it in intermediate risk and only 13% in high risk.
Brachytherapy is hardly used in low risk prostate cancer. It probably needs a reconsideration of recommendations due to the good results in association with a good picking. The urologist-radiotherapist couple is essential in the overall care of the patient.
前列腺癌近距离放射治疗可作为根治性前列腺切除术和放射治疗的替代方法。在低风险组中,10年后的特定生存率高达95%。本研究的目的是描述法国近距离放射治疗的实践情况。
法国泌尿外科学会(AFU)和法国肿瘤放射治疗学会(SFRO)进行了一项调查,评估法国近距离放射治疗的实践情况,并将调查问卷发送给了所有泌尿外科医生和放射肿瘤医生,即使他们并不从事该治疗。
总共发放了1417份调查问卷,共收到285份回复,分别来自211名泌尿外科医生(74%)和74名放射肿瘤医生(26%)。其中60人(21%)从事近距离放射治疗(31名泌尿外科医生,29名放射肿瘤医生)。83.3%的人使用低剂量率永久性植入物。回复调查的人中,90%建议对低风险组采用近距离放射治疗,73%对中风险组采用该治疗,而对高风险组仅13%采用。
近距离放射治疗在低风险前列腺癌中很少使用。由于结合良好的筛选取得了良好效果,可能需要重新考虑相关建议。泌尿外科医生 - 放射肿瘤医生的合作对患者的整体护理至关重要。
4级。